Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus

Zarmen Israelian1, Ervin Szoke, Juergen Woerle

  • 1Department of Endocrinology, Carl T. Hayden VA Medical Center, Phoenix, AZ 85012, and Department of Medicine, University of Rochester School of Medicine, NY 14642, USA.

Insights

Hormonal responses to hypoglycemia are impaired in type 2 diabetes mellitus (T2DM). Patients with T2DM show delayed insulin secretion and reduced glucagon and growth hormone responses during hypoglycemia.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Diabetes Research

Background:

  • Hormonal counter-regulation during hypoglycemia is critical for glucose homeostasis.
  • Understanding these responses in type 2 diabetes mellitus (T2DM) is crucial due to potential beta-cell dysfunction.
  • Previous studies on growth hormone and insulin secretion during hypoglycemia in T2DM have yielded conflicting results.

Purpose of the Study:

  • To compare hormonal responses, including insulin secretion rates, during a hyperinsulinemic hypoglycemic clamp in individuals with and without T2DM.
  • To investigate beta-cell function and counter-regulatory hormone release in response to experimentally induced hypoglycemia in T2DM.

Main Methods:

  • A 2-hour hyperinsulinemic hypoglycemic clamp was performed in nondiabetic subjects (n=21) and individuals with T2DM (n=14) matched for age, sex, and BMI.
  • Baseline glycemia was controlled overnight using a variable insulin infusion.
  • Hormonal levels (insulin, glucagon, growth hormone, epinephrine, norepinephrine, cortisol) and glucose levels were measured throughout the clamp procedure.

Main Results:

  • Subjects with T2DM exhibited a significantly slower decline in insulin secretion (time to half baseline: 38.9 vs 22.3 min, P<.01) and a lesser overall decrease compared to controls.
  • Responses of glucagon (28.3 vs 52.8 ng/L, P<.05) and growth hormone (2.9 vs 6.3 ng/mL, P<.04) were significantly reduced in the T2DM group.
  • Epinephrine, norepinephrine, and cortisol responses were comparable between the groups.

Conclusions:

  • Individuals with T2DM and moderate beta-cell failure demonstrate multiple defects in hormonal responses to hypoglycemia.
  • These defects include delayed and attenuated insulin secretion, alongside impaired counter-regulatory responses of glucagon and growth hormone.
  • These findings highlight the complex dysregulation of glucose metabolism during hypoglycemia in T2DM.

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...